Consainsights logo
Mail Us
Reports > Life Sciences > Preimplantation Genetic Testing Market Report

Preimplantation Genetic Testing Market Size, Share, Industry Trends and Forecast to 2033

This report provides comprehensive insights into the Preimplantation Genetic Testing market from 2023 to 2033, analyzing key trends, regional dynamics, market size, and growth opportunities. The data aims to guide stakeholders in making informed decisions.

Metric Value
Study Period 2023 - 2033
2023 Market Size $1.80 Billion
CAGR (2023-2033) 7.2%
2033 Market Size $3.68 Billion
Top Companies RMA of New Jersey, Illumina, Inc., CooperSurgical, Inc., Next Generation Genomics, LLC, Genea Limited
Last Modified Date 15 Nov 2024

Preimplantation Genetic Testing Market Report (2023 - 2033)

Preimplantation Genetic Testing Market Overview

The Preimplantation Genetic Testing industry is characterized by rapid evolution and technological shifts. Innovations in sequencing technology, such as next-generation sequencing (NGS), continue to enhance the accuracy and efficiency of genetic testing. The proliferation of fertility clinics and research laboratories has expanded access to PGT services, making it more accessible to a wider range of patients. Additionally, collaborations between biotechnology companies and fertility clinics are on the rise, driving advancements in testing methodologies. However, ethical considerations and regulatory compliance maintain a challenging landscape for industry players.

What is the Market Size & CAGR of Preimplantation Genetic Testing market in 2023?

In 2023, the global Preimplantation Genetic Testing market is estimated to reach approximately USD 3.30 billion, with a projected compound annual growth rate (CAGR) of 7.6% from 2023 to 2033. This growth is fueled by technological advancements in genetic testing, increasing public awareness and acceptance of genetic screening, and the rising prevalence of infertility and genetic disorders globally. Factors such as supportive governmental policies and ongoing research in reproductive genetics will further enhance the market size.

Preimplantation Genetic Testing Industry Analysis

The Preimplantation Genetic Testing industry is characterized by rapid evolution and technological shifts. Innovations in sequencing technology, such as next-generation sequencing (NGS), continue to enhance the accuracy and efficiency of genetic testing. The proliferation of fertility clinics and research laboratories has expanded access to PGT services, making it more accessible to a wider range of patients. Additionally, collaborations between biotechnology companies and fertility clinics are on the rise, driving advancements in testing methodologies. However, ethical considerations and regulatory compliance maintain a challenging landscape for industry players.

Preimplantation Genetic Testing Market Segmentation and Scope

The global Preimplantation Genetic Testing market is segmented based on technique, application, end-user, and process. Key segments include PGT-A, PGT-M, and PGT for structural rearrangements. The market is also categorized by end-users, including fertility clinics, hospitals, and research laboratories. This segmentation highlights the varied applications of PGT, from fertility preservation to the prevention of genetic disorders, which is essential for targeting specific needs within the population.

Request a custom research report for industry.

Preimplantation Genetic Testing Market Analysis Report by Region

Europe Preimplantation Genetic Testing Market Report:

The European market is anticipated to increase from USD 0.47 billion in 2023 to USD 0.97 billion in 2033. Countries like Germany and the UK showcase robust growth due to established healthcare systems and comprehensive genetic testing frameworks.

Asia Pacific Preimplantation Genetic Testing Market Report:

In the Asia Pacific region, the market is estimated to grow from USD 0.35 billion in 2023 to USD 0.72 billion in 2033. The region is witnessing increasing investments in healthcare and advancements in reproductive health technologies, alongside rising awareness of genetic testing services among the population.

North America Preimplantation Genetic Testing Market Report:

In North America, the PGT market is expected to rise from USD 0.68 billion in 2023 to USD 1.40 billion in 2033. Strong demand for IVF procedures, coupled with higher disposable incomes and advanced healthcare facilities, drives this growth.

South America Preimplantation Genetic Testing Market Report:

The South American market is projected to grow from USD 0.09 billion in 2023 to USD 0.19 billion in 2033. The growth is attributed to improvements in healthcare infrastructure and growing acceptance of assisted reproductive technologies.

Middle East & Africa Preimplantation Genetic Testing Market Report:

In the Middle East and Africa, the market is projected to double from USD 0.20 billion in 2023 to USD 0.41 billion in 2033, primarily due to rising investments in healthcare technology and growing demand for fertility treatments in the region.

Request a custom research report for industry.

Preimplantation Genetic Testing Market Analysis By Technique

Global Preimplantation Genetic Testing Market, By Technique Market Analysis (2023 - 2033)

In 2023, the market for Sample Collection stands at USD 1.19 billion, expected to reach USD 2.43 billion by 2033. DNA Analysis will amount to USD 0.49 billion in 2023 with projections of USD 1.01 billion by 2033. Data Interpretation currently holds USD 0.12 billion, growing to USD 0.24 billion. This showcases the critical importance of these technical stages in the PGT process.

Preimplantation Genetic Testing Market Analysis By Application

Global Preimplantation Genetic Testing Market, By Application Market Analysis (2023 - 2033)

Significant applications include Preimplantation Genetic Diagnosis (PGD) with a market size of USD 1.19 billion in 2023 and projected to be USD 2.43 billion in 2033. Additionally, PGT-A will reach USD 0.49 billion and PGT-M will grow to USD 0.24 billion by 2033, demonstrating a focus on disease prevention and reproductive health strategies.

Preimplantation Genetic Testing Market Analysis By End User

Global Preimplantation Genetic Testing Market, By End User Market Analysis (2023 - 2033)

Fertility Clinics dominate the PGT market, with a size of USD 1.19 billion in 2023, likely to grow to USD 2.43 billion by 2033. Research Laboratories and Hospitals also represent significant shares, highlighting the essential role of diverse healthcare settings in PGT service delivery.

Preimplantation Genetic Testing Market Analysis By Process

Global Preimplantation Genetic Testing Market, By Process Market Analysis (2023 - 2033)

The segmentation by process indicates that In Vitro Fertilization (IVF) retains a substantial market presence, currently valued at USD 1.19 billion and expected to maintain similar growth. Fertility Preservation and Genetic Disorders also show promising growth trajectories, reflecting the diverse uses of PGT technology.

Preimplantation Genetic Testing Market Trends and Future Forecast

Looking ahead to 2033, the PGT market is expected to witness sustained growth driven by innovations in genetic technology, a rising prevalence of infertility, and policy support from governments promoting genetic research. Challenges such as ethical considerations and regulatory limitations may temper growth but overall opportunities in emerging markets are likely to drive expansion. Advances in AI and machine learning for genomic analysis also present new avenues for expertise and service efficiency within PGT. The market is set for dynamic change and adaptation in response to evolving consumer expectations and technological advancements.

Request a custom research report for industry.

Global Market Leaders and Top Companies in Preimplantation Genetic Testing Industry

RMA of New Jersey:

A leader in reproductive medicine and genetic testing services, providing advanced PGT solutions to enhance IVF outcomes.

Illumina, Inc.:

Pioneers in the field of genomic sequencing, Illumina’s technology is widely used in PGT for efficiently assessing embryonic genetic conditions.

CooperSurgical, Inc.:

This company offers a comprehensive range of reproductive health solutions, including diagnostic tools that support PGT procedures.

Next Generation Genomics, LLC:

A biotechnology firm specializing in NGS services pertinent to PGT, focusing on increasing the reliability and ease of genetic testing.

Genea Limited:

Renowned for its leading fertility clinics, Genea provides extensive genetic testing options to improve patient IVF outcomes through effective genetic screening.

We're grateful to work with incredible clients.

Datasite
Agilent
Asten Johnson
Bio-Rad
Carl Zeiss
Dywidag
Illumina
LEK Consulting
Shell

Related Industries

    FAQs